Nexplanon causes irregular bleeding because its steady release of progestin changes the lining of your uterus in ways that make small blood vessels fragile and prone to leaking. This is the most common side effect of the implant, and roughly two-thirds of users experience prolonged bleeding in the first three months. The good news: for most people, it improves significantly over time.
What Progestin Does to Your Uterine Lining
In a normal menstrual cycle, estrogen and progesterone rise and fall in a predictable pattern. Estrogen thickens the uterine lining, progesterone stabilizes it, and when both hormones drop, the lining sheds in an organized way. That’s your period.
Nexplanon disrupts this cycle by delivering a constant, low dose of a synthetic progestin called etonogestrel. Without the usual hormonal ebb and flow, your uterine lining becomes thin and fragile rather than thick and stable. The tiny blood vessels within the lining respond in several problematic ways: they grow larger, their walls become thinner, and over time they lose structural integrity. Instead of the lining shedding cleanly in one event, these weakened vessels leak small amounts of blood unpredictably.
The Biology Behind the Bleeding
Researchers have identified several overlapping mechanisms that explain why continuous progestin exposure leads to breakthrough bleeding. None of them act alone; it’s the combination that creates the problem.
First, the blood vessels themselves change. Under constant progestin, endometrial vessels develop thin walls and expanded openings. Studies in animal models show these vessels begin losing structural integrity within about two weeks of progestin exposure, with visible signs of hemorrhage (clusters of red blood cells leaking into surrounding tissue) appearing shortly after. Interestingly, the density of blood vessels increases in the thinned lining, but vessel density alone doesn’t predict bleeding. It’s the fragility and poor function of those vessels that matters more.
Second, the body’s tissue-remodeling enzymes get activated at the wrong times. Proteins called matrix metalloproteinases, which normally break down the uterine lining only during menstruation, become selectively activated in response to continuous progestin. Immune cells, particularly neutrophils, infiltrate the tissue and release these enzymes along with other inflammatory chemicals, causing localized breakdown of the lining in small patches rather than all at once.
Third, factors that control blood vessel growth and clotting become altered. Signaling molecules that promote new vessel formation increase in the endometrium of implant users, and a key clotting factor is elevated specifically at bleeding sites compared to non-bleeding areas. This suggests the lining is actively trying to repair itself but doing so in a disorganized way that contributes to ongoing spotting.
A fourth piece involves specialized immune cells called uterine natural killer cells, which appear in high numbers in progestin-modified tissue. These cells are associated with tissue changes that can trigger bleeding episodes, adding yet another layer to the disruption.
What Bleeding Patterns Look Like Over Time
The first three to six months are typically the worst. About 66% of implant users experience prolonged bleeding in the first 90-day period after insertion. By the end of three years, that number drops to roughly 27%.
In the first three months, about one-third of users settle into a favorable bleeding pattern (28 or fewer days of spotting or bleeding per 90-day window), and that pattern usually continues for the remaining two years of use. Another third develop favorable patterns during months three through six. After six months, however, roughly one-third of users still have unfavorable patterns like frequent or prolonged bleeding.
Higher levels of etonogestrel in the blood are associated with more unfavorable bleeding, which partly explains why bleeding tends to improve over time as hormone levels gradually decrease from the implant. Some users stop having periods entirely, while others shift to light, infrequent spotting. The challenge is that there’s no reliable way to predict which pattern you’ll fall into before trying the implant.
Managing Persistent Bleeding
If your bleeding doesn’t settle on its own, there are short-term treatments that can help. These won’t permanently fix the problem, but they can provide relief during rough stretches, and they can be repeated as needed.
- Anti-inflammatory medications: Ibuprofen or mefenamic acid taken for five to seven days can reduce bleeding. NSAIDs work by suppressing the inflammatory processes contributing to vessel leakiness, and their effects may persist for some time after you stop taking them.
- Short courses of estrogen: A low-dose combined oral contraceptive pill (containing 20 to 30 micrograms of estrogen) taken temporarily can stabilize the fragile uterine lining. This provides the estrogen your body isn’t getting from the progestin-only implant, essentially patching up those leaky vessels. The improvement is temporary and typically lasts only while you’re taking the pill.
- Anti-bleeding medications: Tranexamic acid, taken for about five days, helps by supporting the blood-clotting process in the uterine lining. This also provides temporary relief.
About 27% of implant users report bothersome bleeding at some point during use. Among those who needed medication to manage their bleeding, over half still kept the implant for the full three years. That’s worth knowing if you’re in the middle of a frustrating bleeding stretch and wondering whether to stick it out: the odds are better than even that things will improve enough to keep the implant.
Why Some People Bleed More Than Others
Individual variation in bleeding comes down to how your specific uterine lining responds to continuous progestin. The thickness and composition of your endometrium before insertion, your baseline hormone levels, and how your immune system responds to the hormonal shift all play a role. Some people’s endometrial tissue adapts quickly, suppressing vessel growth and stabilizing within weeks. Others have a more prolonged inflammatory response, with ongoing enzyme activation and vessel fragility that takes months to settle.
The type of bleeding also varies. Some users experience light but near-constant spotting (small amounts of blood from multiple leaky vessels across the lining). Others have episodes of heavier bleeding that mimic short periods, caused by more concentrated areas of tissue breakdown. Both patterns reflect the same underlying mechanism, just playing out differently depending on individual biology.